Nicole White
Corporate Officer/Principal bei ASSEMBLY BIOSCIENCES, INC.
Vermögen: 171 716 $ am 30.04.2024
Aktive Positionen von Nicole White
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. | Corporate Officer/Principal | 17.11.2020 | - |
Karriereverlauf von Nicole White
Ehemalige bekannte Positionen von Nicole White
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| GOSSAMER BIO, INC. | Corporate Officer/Principal | 01.05.2018 | 01.11.2020 |
Abide Therapeutics, Inc.
 Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01.10.2015 | 01.04.2018 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01.03.2009 | 01.10.2015 |
Ausbildung von Nicole White
| University of California, Irvine | Doctorate Degree |
| University of California San Diego | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 7 |
Operativ
| Corporate Officer/Principal | 4 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ASSEMBLY BIOSCIENCES, INC. | Health Technology |
| GOSSAMER BIO, INC. | Health Technology |
| GILEAD SCIENCES, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Health Technology |
- Börse
- Insiders
- Nicole White
- Erfahrung
